(0.15-1.5 M). Fractions rich in EPO activity were pooled and dialyzed against PBS (8.1 mM Na 2 PO 4 , 1.5 mM KH 2 PO 4 , 137 mM NaCl, 2.7 mM KCl (pH 7.40)) and concentrated. The concentrated solution was centrifuged, and the supernatant was removed and frozen at Ϫ70°C. All preparations of EPO had absorbance ratios (absorbance at 412 nm/absorbance at 280 nm) between 0.95 and 1.04.
Fractions from the Sephadex G-50 column containing ECP and EDN were pooled, dialyzed against one-half concentration PBS (pH 7.4), concentrated, and fractionated on a heparin-Sepharose CL-6B column (1.2 ϫ 8 cm) equilibrated with one-half concentration PBS. Proteins bound to the column were eluted with a linear NaCl gradient (0.07-1.5 M NaCl). EDN eluted at a low salt concentration (ϳ0.2 M NaCl), whereas ECP eluted at ϳ0.4 M NaCl (14) . Extinction coefficients at 280 nm of 1.64 (mg/ ml) Ϫ1 cm Ϫ1 for EDN and 1.55 (mg/ml) Ϫ1 cm Ϫ1 for ECP were used to determine protein concentrations (14) . To obtain ECP1 and ECP2 (14) , two forms of differentially glycosylated ECP, ECP fractions pooled from the initial heparin-Sepharose column were subjected to a second heparinSepharose chromatography. These latter fractions were analyzed by SDS-PAGE followed by colloidal Coomassie blue staining (GelCode Blue; Pierce), and ECP1 and ECP2 were pooled separately.
Fractions containing MBP1 (2, 29) from the Sephadex G-50 column were pooled and stored at Ϫ70°C in 0.025 M sodium acetate, 0.15 M NaCl (pH 4.2) to inhibit polymerization. MBP1 concentrations were determined using an extinction coefficient at 277 nm of 2.63 (mg/ml) Ϫ1 cm Ϫ1 (26) . Use of a more recently determined extinction coefficient (3.67 (mg/ml) Ϫ1 cm
Ϫ1
) would have resulted in 28% lower calculated MBP1 concentrations (2) . The original calculations were used throughout the study for consistency with other granule protein concentrations. All eosinophil granule protein preparations were pure as assessed by Coomassie blue staining following SDS-PAGE.
RNase activity and lesion formation
To test the influence of RNase activity on ECP and EDN lesion formation, injectable-grade RNasin, an RNase inhibitor that effectively inhibits the RNase activity of EDN (15) , was mixed with ECP and EDN for a final concentration of 3.3 M protein and 17 M RNasin (64 g of 78 U/g RNasin in a final volume of 75 l) just before intradermal injections of each mixture into two guinea pigs. For comparison, ECP or EDN mixed with sterile PBS in place of the RNasin was also injected.
To test further the effect of RNase activity, 1 mg of purified ECP or EDN was diluted in 200 mM MES, 167 mM NaCl (pH 5.5) and carboxymethylated by incubating with 75 mM sodium iodoacetate (Sigma-Aldrich) at 37°C for 5 h in the dark (15) . As controls, a "sham" carboxymethylation procedure without addition of sodium iodoacetate was performed with purified ECP or EDN, and these products are referred to as unmodified-ECP and unmodified-EDN. After incubation, the samples were diluted 10-fold with 8.1 mM Na 2 PO 4 , 1.5 mM KH 2 PO 4 (pH 7.4) ("no salt" PBS) and loaded onto a heparin Sepharose CL-6B column (Amersham Biosciences) equilibrated with no salt PBS. The column was washed with no salt PBS and a gradient from 0 to 430 mM NaCl in PBS was initiated. Absorbance at 280 nm of collected fractions (to estimate protein content) and RNase activity of selected peak fractions (see "RNase activity measurement" below) were measured. This procedure resulted in carboxymethylated ECP (CM-ECP) and CM-EDN that eluted from the heparin-Sepharose column at somewhat lower salt concentrations and that had RNase activity diminished by 80 -90%, based on the change in initial RNase velocity.
Intradermal injections and their assessment
The Institutional Animal Use and Care Committee approved the studies. Hartley guinea pigs, 400 -600 g, were anesthetized with 100 mg/ml ketamine hydrochloride containing 1% xylazine (Ketaset; Fort Dodge Laboratories) by i.m. injections of 0.5 ml per kilogram body mass. Fifty or 90 l of ECP, EDN, EPO, and MBP1 at concentrations ranging from 0.5 to 50 M prepared in sterile buffers using LPS-free water (sterile water for irrigation (USP); Baxter Healthcare) was injected intradermally into shaved back skin. Sterile acetate buffer (0.025 M sodium acetate, 0.15 M NaCl (pH 4.2); MBP1 storage buffer), phosphate buffer with 1 M NaCl (elution and storage buffer for ECP, EDN, and EPO with a NaCl concentration greater than or equal to that needed to elute each of these proteins from their respective cation exchange columns during purification), and sterile PBS were also injected. Additional intradermal injections included poly-L-arginine hydrochloride (5-15 kDa), bovine RNase A, and LPS (from Escherichia coli J5) from Sigma-Aldrich. Injectable grade RNasin was from Promega. Pyroglu-angiogenin (Ang) was provided by Dr. R. Shapiro (Harvard Medical School, Boston, MA). To determine that the injection-site reactions were not species-restricted, rabbits were also tested.
Injection sites were examined at least twice weekly. Lesions were assessed for appearance using the grading scale: 0, no visible or palpable lesion; 0.5, trace visible erythema, edema, and/or palpable lesion; 1, visible erythema, edema with a palpable lesion; 2, erythematous, edematous, indurated palpable lesion; 3, palpable lesion with induration and mainly nonerosive epidermal changes (epidermal disruption with Ͻ50% of lesion eroded or ulcerated); 4, induration with crusting or ulceration (Ͼ50% of lesion). For skin biopsy collection, animals were killed by intracardiac injection of pentobarbital (Nembutal), and biopsies were immediately obtained by gently lifting the skin and using curved scissors to cut around the injection sites. Twenty-two guinea pigs and two rabbits were used in the studies; not all were tested with the same injections at the same time. The number tested is listed in each table for the respective experiments.
Indirect immunofluorescence and histologic staining
Human ECP, EDN, EPO, and MBP were detected in formalin-fixed, paraffin-embedded biopsy specimens of cutaneous injection sites by indirect immunofluorescence. Briefly, serial tissue sections (5 m) were mounted on positively charged microscope slides, deparaffinized, and incubated in 0.1% trypsin for 1 h at 37°C. The slides were incubated overnight in 10% normal goat serum at 4°C. The next day, sections were washed and overlaid with either control rabbit Ab (normal rabbit IgG or rabbit preimmunization serum) or granule protein-specific Ab (affinity chromatographypurified rabbit anti-human EDN and MBP or rabbit antiserum against ECP and EPO, all produced in our laboratory). Slides were washed and treated with 1% chromotrope 2R (J. T. Baker) to eliminate nonspecific eosinophil staining (30) . Subsequently, slides were overlaid with FITC-conjugated goat anti-rabbit IgG (SouthernBiotech). After a final wash, sections were mounted in a glycerol solution containing p-phenylenediamine to prevent fading (31) . Representative photomicrographs were taken with a Zeiss Axiophot microscope equipped with excitor barrier filter set: blue BP450/490-LP520/560 (N 487910). Histologic examination with H&E stains was also performed to examine cellular infiltration.
RNase activity measurement
Mouse liver RNA was isolated using RNA-STAT protocol (Tel-Test) and quantitated by absorbance at 260 nm. RNA was stored in 1ϫ Tris-acetate-EDTA buffer (40 mM Tris-acetate, 1 mM EDTA (pH 8.3) in diethylpyrocarbonate-treated sterile H 2 O). To assay for RNase activity (32), stock YOYO-1 dye (1 mM; Invitrogen) was added to 10 g/ml mouse liver RNA in Tris-acetate-EDTA buffer to a final YOYO-1 concentration of 2 M, and this solution was heated at 65 o C for 10 min. This RNA/YOYO-1 solution (100 l) was added to the wells of a polystyrene flat-bottom 96-well plate and measured using a Cytofluor plate reader series 4000 (PerSeptive Biosystems) with excitation at 485 nm and emission at 530 nm. The RNA/YOYO-1 complex was allowed to equilibrate for 1 h before addition of protein (EDN, ECP, RNase A, or Ang) to duplicate wells, and fluorescence readings were recorded. Initial RNase velocity values were calculated from the change in arbitrary fluorescence units occurring from 2 to 4 min after the addition of protein and normalized per mass of protein added.
Results

Cutaneous lesion formation
Reducing SDS-PAGE was used to assess the purity of the eosinophil granule protein preparations (Fig. 1 ). Fig. 2 shows representative lesions following eosinophil granule protein injection, with robust lesions from ECP and EDN, and less intense or no lesions from EPO, MBP1, and bovine RNase A. In this experiment, granule proteins at 10 M and 2.5 M and their storage buffer solutions were injected intradermally, and injection sites were observed for up to 4 wk; Table I shows the lesion grade for each granule protein. Overall, ECP induced the most severe lesions, followed by EDN; both ECP and EDN had greater lesion-forming activity than did EPO or MBP1. ECP lesions were distinctly and consistently ulcerative, and EDN lesions typically showed white, dry crusts (Fig. 2 ). ECP and EDN lesion formation began within 2 days and peaked ϳ7 days after injection (Table I) . Injection sites of identical samples on duplicate guinea pigs were similar in magnitude and appearance, while the overall severity of the 2.5 M injection sites was diminished relative to the 10 M sites (Table I) . Bovine RNase A, sterile PBS, and phosphate buffer with 1 M NaCl injection sites did not cause lesions after injection (Fig. 2) . Undiluted acetate buffer caused a trace lesion (0.5 score) that returned to normal after 1 wk. However, for control purposes, this was an extreme acetate buffer concentration because the stock MBP1 in acetate buffer was diluted Ͼ20-fold with sterile PBS before injection. Intradermal injections of the granule proteins at 25 M were also performed in two rabbits. Similar lesion formation occurred except that lesions from EPO were relatively more intense and approached the severity of lesions from EDN (Table I) .
Additional experiments were performed with a wider range of ECP and EDN concentrations. Lesions were consistently elicited with Ն2.5 M ECP or EDN, and visible lesions frequently formed even at 1 M ECP or EDN. Lesions remained detectable for Ͼ2 wk with Ն2.5 M ECP or EDN (Table I) . Alopecia persisted at least 4 wk at 10 EDN injection sites (two 9 M and eight 10 M) on four guinea pigs. The 10 M EDN injection sites on one guinea pig were monitored up to 6 wk after injection and showed hair regrowth at this time. Alopecia and crusting persisted longer than 4 wk at three ECP injection sites (all 10 M) on each of two guinea pigs.
To rule out a potential contribution from bacterial or LPS contamination in purified eosinophil granule protein preparations, three approaches were taken. First, purified LPS at concentrations up to 100 g/ml was intradermally injected into guinea pigs. Lesion-forming activity by endotoxin was minimal, never exceeding a trace lesion (0.5 score), even at 100 g/ml, from 2 to 14 days after injection. Second, to avoid bacterial contamination of injected protein samples, all samples were centrifuged at 12,000 ϫ g for 10 min before injection, and only the supernatants were injected. A supernatant sample of ECP was tested for bacterial contamination by culture at the Mayo Clinic Microbiology Laboratory, and no microorganisms were detected after 5 days of culture. Finally, to rule out a pathogenic bacterial infection, a representative lesion induced by ECP was biopsied, and a portion was cultured. Testing was performed on both agar plates and in liquid broth; coagulasenegative Staphylococcus and Streptococcus viridans, likely commensal organisms, were cultured from the biopsy.
Mechanism of ECP-and EDN-induced cutaneous lesion formation Cellular localization of ECP and EDN and cellular infiltration.
Within 24 h after ECP injection, heterophil and lymphomononuclear subdermal cell infiltrates were prominent in the dermis, including near cutaneous trunci muscles, and these infiltrates remained substantial 2, 3, and 4 days after injection (Figs. 3, A and  B) . Cellular infiltration increased in the upper dermis during this time and peaked at approximately day 7; cell infiltrates began to decrease at approximately day 14. Similar patterns of cellular infiltration occurred for the other three granule proteins, but with intensities proportional to the lesion-forming activities of the granule proteins (i.e., less cellular infiltration with decreased lesion formation). Likewise, intradermal injection of PBS and RNase A, neither of which induced a skin lesion, resulted in minimal or no detectable cellular infiltration during the first week.
Immunofluorescence staining showed that most of the intradermally injected ECP and EDN, diffusely distributed in tissues initially after injection (Fig. 3C ), were associated with cells in the dermis within 48 h (Fig. 3D-F) . In contrast, EPO and MBP1 remained primarily extracellular and appeared to bind to dermal matrix fibers (Fig. 3, G and H) (5) . Differential glycosylation. Glycosylation influences protein recognition and activity, and because of heterogeneous glycosylation, ECP exists in two predominant forms, that is, ECP1 and ECP2 (14) . Therefore, a sample of ECP containing a mixture of ECP1 and ECP2 was subjected to a second heparin-Sepharose chromatographic separation with NaCl gradient elution. SDS-PAGE analyses showed fractions containing predominantly the higher molecular mass ECP1 or the lower molecular mass ECP2 that eluted FIGURE 1. Purity of eosinophil granule proteins. A, An excess of each of the four eosinophil granule proteins was assessed using SDS-PAGE under reducing conditions. EPO is composed of both heavy (ϳ50 kDa) and light (ϳ10 kDa) chains, and the arrowhead points to the most prominent, more highly glycosylated forms of EDN and ECP in their respective lanes (14) . B, CM-ECP and unmodified ECP (unmod-ECP) after elution from a second heparin-Sepharose CL-6B column was analyzed by SDS-PAGE under reducing conditions. Note that a greater proportion of the lower ECP-2 band is likely present in the unmod-ECP lane because the peak of unmodified ECP, which was from exactly the same ECP sample as that used to generate the CM-ECP, eluted across two main fractions, and it was the latter of these fractions (no. 16; i.e., f16) that was used for this SDS-PAGE. from the heparin-Sepharose column at lower and higher salt concentrations, respectively, and that displayed an ϳ2 kDa difference in SDS-PAGE mobility. Intradermal injections of unseparated ECP, ECP1, and ECP2 at 10 and 2.5 M resulted in lesions of similar severity among the 10 and 2.5 M injections, respectively. These injection sites were biopsied 1 wk later and stained by immunofluorescence for ECP. For all three ECP preparations, specific staining was detected, and the majority of staining appeared localized to cells. Net cationic charge. The limited lesion-forming activity of MBP1 (13.8 kDa, ϩ16 net positive charge) suggested that strong cationic charge is not sufficient to induce cutaneous lesions as intense as those caused by ECP or EDN. Similarly, intradermally injected poly-L-arginine at concentrations up to 25 M showed a maximum of a grade 1 lesion that subsided to a trace lesion after 1 wk. The influence of protein net cationic charge on lesion formation was also examined by injecting RNases of different charges. Ninety microliters of ECP (10 M), EDN (10 M), Ang (10 M), and RNase A (15 M) was each injected intradermally in duplicate into two guinea pigs. To address further the role of RNase activity in lesion formation, an active site histidine of ECP and EDN was carboxymethylated. We first confirmed the relative RNase activities of ECP, EDN, Ang, and RNase A (Fig. 4A) . Following sham treatment or treatment with 75 mM iodoacetate, samples of the unmodified (sham-treated) and CM-ECP or EDN were reisolated by heparin-Sepharose chromatography. Peak fractions of unmodified-ECP, unmodified-EDN, CM-ECP, and CM-EDN were tested for RNase activity; carboxymethylation reduced the RNase activity of ECP and EDN by ϳ80 and 87% (Fig. 4B) , respectively. Carboxymethylation of ECP and EDN strikingly reduced lesion-forming activities by two to three grades both on days 3 and 7 (Table III) . Immunofluorescence staining for ECP at injection sites of unmodified-and CM-ECP at day 3 demonstrated that carboxymethylation did not alter the cellular localization or the overall immunofluorescence distribution of FIGURE 2. Cutaneous lesions induced by eosinophil granule proteins in guinea pig skin. Fifty microliters of proteins, each at 10 M, was injected intradermally. Proteins were injected to the right of the numeric labels and included MBP1 (1), ECP (2), EDN (3), EPO (4), and bovine RNase A (5). Seven days after injections, the guinea pig was anesthetized and photographed as shown.
FIGURE 3. Immunofluorescence localization of ECP and EDN following intradermal injection. H&E staining of the epidermis and upper dermis (A)
and the subdermal area surrounding the trunci muscle (B) 3 days after injection of 10 M ECP (magnification, ϫ200) shows prominent cellular infiltration in the dermis. Immunofluorescence staining for EDN in the dermis less than 1 h (C), 2 days (D), and 4 days (E) after intradermal injection at 10 M (magnification, ϫ400) shows generally diffuse deposition on cells and tissues (C) at 1 h, whereas the later injection sites (D and E) show an increased proportion of cell-localized staining. Immunofluorescence staining for ECP (F), EPO (G), and MBP1 (H) 4 days after intradermal injection at 10 M (magnification, ϫ400) shows relatively greater cellular staining for ECP, similar to EDN, compared with the predominantly extracellular staining for EPO and MBP1. the protein (Fig. 5) ; immunofluorescence staining patterns were similar for unmodified-EDN and CM-EDN.
Relationship to human skin disease
Morphologically, the lesions resulting from ECP and EDN injections into guinea pig skin showed similarity to erosive and ulcerative lesions in patients with HES ( Fig. 6A-C) (33) . Immunofluorescence staining of lesional tissue from four such patients demonstrated both cellular localization and extracellular deposition of ECP and EDN (Fig. 6, D and F) , similar to that observed in guinea pig skin at different time points following intradermal protein injections (Fig. 3) , with the exception that the human tissue showed staining of intact eosinophils. The MBP1 cellular staining, as represented by brightly fluorescent ovals, reflects the relative numbers of intact eosinophils (Fig. 6E ). Both EDN (Fig. 6F ) and especially ECP (Fig. 6D ) staining shows more extensive cellular localization than accountable by MBP1-associated eosinophil staining, suggesting their localization to cells other than eosinophils.
Discussion
Eosinophil granule protein deposition occurs in a variety of dermatoses (4). Several of the granule proteins induce a cutaneous whealand-flare reaction and increase cutaneous vasopermeability in vivo (5, 19, 20) . The in vitro cytotoxicity of eosinophil granule proteins is also well documented (1). Additionally, the hypereosinophilic syndromes are often associated with cutaneous lesions (34) , and atopic dermatitis shows strong association with eosinophil activity (35, 36) . Even so, other reports suggest that eosinophils have a limited impact on asthma and atopic dermatitis inflammation (21) (22) (23) (24) . To help clarify these issues, we investigated the effects of eosinophil granule proteins on guinea pig and rabbit skin through injections into the dermis, a site to which the granule proteins localize in cutaneous diseases. Intradermal injection of micromolar concentrations of four eosinophil granule proteins, ECP, EDN, EPO, and MBP1, produced cutaneous lesions with cellular infiltration. The ECP-and EDN-induced lesions were substantially more pronounced than the EPO-and MBP1-induced lesions. This was unexpected for EDN because of its limited in vitro cytotoxicity toward K562 cells relative to that of ECP, EPO, and MBP1 (2). The lesion-forming activity of ECP and EDN was associated with their localization in dermal cells. Furthermore, RNase activity appears important to their lesion-forming activities, and their respective net positive charges also may have modulated lesion formation. However, neither RNase activity nor high net positive charge alone was sufficient to account for full lesion formation.
The marked lesion-forming activities of ECP and EDN focused our attention on these proteins (Fig. 2 ). An initial concern was whether a contaminant or an infectious component might have contributed to lesion formation. Because lesion-forming activity varied among the different granule proteins and was consistent for a given granule protein, we think that no systematic factor or contaminant was substantially contributing to EDN-and ECP-induced lesions. Several approaches, addressing potential endotoxin or bacterial contamination of the protein preparations and postinjection infection, showed that bacterial or endotoxin contamination did not explain EDN-and ECPinduced lesions. Finally, the ability of RNasin, a specific RNase inhibitor, to diminish an ECP-induced lesion by ϳ60% and the ability of carboxymethylation to diminish ECP-and EDN-induced lesions (Table III) support the specific lesion-forming activities of ECP and EDN. Notably, RNasin (pI of 4.7) probably did not inhibit an EDNinduced lesion because of the relatively short half-life of the EDNRNasin complex (EDN, ϩ7 net charge) compared with that of angiogenin (ϩ10 net charge) (15) , and presumably to that of ECP (ϩ14 net charge). A short EDN-RNasin half-life compared with that of ECP-RNasin is also consistent with the immunofluorescence detection of intradermally injected EDN, but not ECP, when mixed with RNasin. Overall, it is unlikely that the cutaneous lesions caused by intradermal injections of ECP or EDN are attributable to a contaminating substance or infectious component.
The ECP-and EDN-induced lesions developed over 1 wk, occurred at concentrations as low as 1 M, and occurred in both guinea pig and rabbit skin ( Fig. 2 and Table I ). ECP and EDN concentrations Ͼ1 M are likely deposited in human skin disease (5) . Given the pronounced lesion-forming activities of ECP and EDN, we considered distinctive properties of ECP and EDN compared with the less active lesion-forming EPO and MBP1. Two such properties are neurotoxicity and RNase activity. A third property, distinguishing ECP and EDN from EPO and MBP1, is cellular localization after intradermal injection (Fig. 3) (5) . Cellular localization of ECP and EDN appears consistent with previous observations for another RNase, onconase (37), and with our staining for ECP and EDN compared with MBP1 in HES skin lesions (Fig. 6) . Interestingly, cellular internalization can increase the neurotoxicity of an RNase by 1000-fold (38) . Thus, internalization of ECP and EDN, as suggested by the appearance of the immunofluorescent cells within the dermis containing ECP and EDN (Fig. 3) , might account for the unexpectedly high lesion-forming activity of EDN. Unfortunately, due to the paucity of guinea pig-specific reagents, the identity of the cells accumulating ECP and EDN remains unknown. However, ECP has been observed in macrophage-like dermal cells after house dust mite patch testing of humans (39) , and EDN has recently been reported as an endogenous TLR2-dependent "alarmin" acting on dendritic cells (40) . If EDN binds directly to TLR2, a precedent for it being internalized after ligation exists (41) . Additionally, EDN is chemotactic for dendritic cells and stimulates release of inflammatory mediators, such as IL-8 and TNF-␣ (40, 42) . IL-8 and TNF-␣ can lead to further cell recruitment, the latter, at least in part, via increased endothelial cell adhesion molecule expression (43) , and TNF-␣ induces an inflammatory lesion when injected into rabbit skin (44) . Thus, ECP and EDN appear to be internalized by resident dermal cells and, directly or indirectly via induction of other inflammatory mediators, cause additional cellular infiltration and cutaneous disruption.
Given the potential importance of RNase activity, we examined its influence in ECP-and EDN-induced lesion formation, and two approaches, in addition to the use of RNasin (discussed above), were taken. First, we compared the lesion-forming activities of ECP and EDN to two other RNases, Ang and bovine RNase A. The relative RNase activities for these four RNases against the RNA substrate used in this study (i.e., mouse liver total RNA) were as follows: RNase A was more active than EDN, and these were substantially more active than ECP, which was substantially more active than Ang (Fig. 4) . These relative activities are expected from previous reports. However, the relative lesion-forming activities of ECP and EDN were substantially greater than that of Ang, which was substantially greater than that of RNase A (Table  II) . Therefore, lesion formation does not depend solely and directly on RNase activity. Second, we tested carboxymethylated ECP and EDN, and this treatment strikingly inhibited lesion formation (Table III). Thus, at least for ECP and EDN, RNase activity is required for maximal lesion formation. Because carboxymethylation inserts one negative charge per carboxymethyl group added, these changed molecular charges of the carboxymethylated ECP and EDN could be confounding factors (see below). Also, factors other than RNase activity appear to be involved, because while the RNase activity of ECP is substantially less than that of EDN, ECP produces a more prominent lesion.
Cationicity is often associated with cytotoxicity (45) . Thus, net positive charge, as suggested by the cytotoxic activity of the nonRNase MBP1 (ϩ16, molecular mass of 13.8 kDa) (2), may contribute to lesion formation. For example, a more highly cationic protein may have an increased partitioning to the cell's surface or increased direct cytotoxicity or both. The protein cationicity of the RNases decreases in the following order: ECP, Ang, EDN, and RNase A (Table II) . Because the more highly charged Ang does not produce a more pronounced lesion than that caused by EDN, nor does MBP1 or poly-L-arginine cause such pronounced lesions, a direct relationship between net positive charge and lesion-forming activity does not exist. Glycosylation can affect a protein's net charge, and both ECP and EDN are glycosylated, while Ang and RNase A are not. A recent study showed that the N-linked carbohydrates on ECP are in part made up of sialic acid, galactose, and acetylglucosamine (46) . These individual carbohydrates are suggestive of "complex type" N-linked glycosylation, which typically involves noncharged carbohydrates and negatively charged sialic acid. This form of glycosylation would only diminish ECP's cationicity and presumably any associated cation-dependent cytotoxicity. Alternatively, such glycosylation could confer other properties to ECP and EDN that contribute to their distinct lesionforming capabilities compared with Ang and RNase A, even though differential glycosylation of ECP1 and ECP2 did not noticeably alter their lesion-forming activities.
Thirteen members of the human RNase family have been identified (47) . Among these 13 genes, ECP and EDN form a distinct clad with substantial homology. Thus, unidentified molecular characteristics specific to ECP and EDN may be critical to their cutaneous lesionforming activity. For instance, after intradermal injection, it is unknown whether Ang and RNase A localize to dermal cells like ECP and EDN. However, similar to their difference in lesion-forming potency reported herein, the alarmin adjuvant effect of EDN reported by Yang et al. was not recapitulated by human angiogenin (40) . The relatively specific lesion-inducing activities of ECP and EDN compared with other RNases are also reminiscent of their unique neurotoxic and antiviral activities (48) . Morphologically, the lesions resulting from ECP or EDN injection into guinea pig skin showed similarity to erosive and ulcerative lesions in an HES variant (Fig. 6A-C) that, until recently, was associated with a grave prognosis (33) . HES with ulcerative lesions appears to be a presentation of myeloproliferative HES (associated with a deletion on chromosome 4 resulting in a fusion gene product, FIP1L1-PDGFRA, and yielding a novel kinase sensitive to imatinib mesylate therapy with long-term disease control) (49, 50) . The biopsy specimens from 4 HES patients showed both eosinophil infiltration and eosinophil granule protein deposition; the staining of cell-localized ECP and EDN was extensive, out of proportion to the number of infiltrating eosinophils identified by MBP1 staining, and similar to that observed in guinea pig skin at later time points following injection of ECP and EDN. Ongoing deposition of ECP and EDN in human tissue, unlike single injections of ECP or EDN into guinea pig skin, likely contributed to the relatively greater extracellular staining of ECP and EDN in human tissue compared with later guinea pig intradermal injection sites (Ն 2 days postinjection). Because of ethical considerations, it is not possible directly to study the effects of eosinophil granule proteins injected into human skin; however, these analogous findings by formation of lesions and by immunostaining support the conclusion that ECP and EDN cause cutaneous lesions in human disease.
In summary, all four eosinophil granule proteins, ECP, EDN, EPO, and MBP1, induce a cutaneous lesion after intradermal injection into guinea pig and rabbit skin at pathophysiologically relevant concentrations. The ECP-and EDN-induced lesions are more intense than lesions induced by EPO and MBP1, and this difference appears to be closely associated with cellular internalization and RNase activity of ECP and EDN. Net cationic charge may also modulate lesion-forming activity. However, neither cationicity or RNase activity directly correlates with lesion-forming activity, suggesting the potential importance of other properties specific to ECP and EDN. Overall, these data provide further direct evidence that deposition of the eosinophil granule proteins, particularly ECP and EDN, at micromolar concentrations, can severely effect cutaneous structure and function in diseases in which granule proteins are deposited including in the hypereosinophilic syndrome associated with mucocutaneous ulcerations (Fig. 6) (33, 34, 50 ).
FIGURE 5.
Immunofluorescence staining for intradermally injected unmodified-ECP and CM-ECP. Injection site biopsies were taken from one of three guinea pigs 3 days after injecting unmodified ECP (A) and CM-ECP (B). Polyclonal rabbit anti-ECP was used to stain for ECP in these specimens, and a representative area of the dermis in each shows comparable cellular and extracellular staining (magnification, ϫ160). 
